Skip to content
HFA logo
  • About HFA
    • Our Story
    • Our Team
    • Our Board
    • Our Sponsors
  • Our Work
    • Assisting
    • Educating
    • Advocating
  • Learn
    • History of Bleeding Disorders
    • Bleeding Disorders 101
    • Learning Central
  • Financial Assistance
    • Helping Hands
      • Emergency Assistance
      • Items Assistance
      • Inhibitor Support
      • Disaster Relief
    • Job Readiness Grants
    • Scholarships
  • Get Connected
    • Join Blood Sisterhood
    • Join Blood Brotherhood
    • Join Sangre Latina
    • Contact Your Legislator
    • Apply for an Internship
    • Become a Member
  • Locate
    • Member Organizations
    • Hemophilia Treatment Centers
    • Summer Camps
  • Resources
  • Events
    • All Events
    • Symposium
  • News
  • Donate
Menu
  • About HFA
    • Our Story
    • Our Team
    • Our Board
    • Our Sponsors
  • Our Work
    • Assisting
    • Educating
    • Advocating
  • Learn
    • History of Bleeding Disorders
    • Bleeding Disorders 101
    • Learning Central
  • Financial Assistance
    • Helping Hands
      • Emergency Assistance
      • Items Assistance
      • Inhibitor Support
      • Disaster Relief
    • Job Readiness Grants
    • Scholarships
  • Get Connected
    • Join Blood Sisterhood
    • Join Blood Brotherhood
    • Join Sangre Latina
    • Contact Your Legislator
    • Apply for an Internship
    • Become a Member
  • Locate
    • Member Organizations
    • Hemophilia Treatment Centers
    • Summer Camps
  • Resources
  • Events
    • All Events
    • Symposium
  • News
  • Donate
Search

Day: October 7, 2020

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

The following is an excerpt from a statement from Pfizer. Read the statement in its entirety here. AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A. The primary endpoint is impact on annual bleed rate […]

Helpful Links

  • Contact HFA
  • Careers
  • DEI Statement
  • Financials & Reports
  • Funding Policies
  • Privacy Policy
  • Contact HFA
  • Careers
  • DEI Statement
  • Financials & Reports
  • Funding Policies
  • Privacy Policy

Sign up for our news and updates

Facebook Instagram Twitter Linkedin Youtube

© 2023 Hemophilia Federation of America | Site powered by HFA Staff